🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

SURAKSHA DIAGNOSTIC LTD SURAKSHA NSEPHARMA

Healthcare · Diagnostics & Research · India
https://www.surakshanet.com
Company Profile ↓
₹261.75
-18.31% 1Y
Mkt Cap₹1,363.21 Cr
P/E43.84
P/B5.53
Div. Yield0.19%
52W High₹327.90
52W Low₹227.95
Book Value₹47.01
EPS (TTM)₹5.97

Company Overview

Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 70.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 17.7% CAGR over the past five years.

Healthy Margins

Operating margin of 17.5% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹310.41 Cr (+23.1% YoY); net profit ₹32.19 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +23.1%, earnings +1.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 17.7%, profit CAGR 70.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:17.75%
1 Year:23.13%

Compounded Profit Growth

5 Years:70.31%
1 Year:1.14%

Stock Price Performance

1 Year:-18.31%
6 Months:-2.60%
3 Months:-6.53%
1 Month:-2.42%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 34% of range
₹227.95 ₹327.90
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • Death Cross9d ago
  • RSI (14)39.00 · Neutral
Price Performance
1M-2.42%
3M-6.53%
6M-2.60%
1Y-18.31%
Valuation vs Sector

P/E of 43.84 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 17.7% over 5 years.
  • Profit CAGR of 70.3% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
43.84
Industry PE
39.97
Forward P/E
28.45
PEG Ratio
-
Book Value
₹47.01
Price to Book
5.53
P/S
4.38
EV/EBITDA
15.20
Dividend Yield
0.19%

Growth (CAGR)

Revenue 5Y
17.75%
Profit 5Y
70.31%
Revenue (YoY)
23.13%
Earnings (YoY)
1.14%

Profitability & Returns

ROCE
14.70%
ROE
13.15%
ROA
7.18%
Profit Margin
10.37%
Op Margin
17.53%
Gross Margin
88.25%
EPS (Latest Qtr)
₹1.21
EPS (TTM)
₹5.97

Balance Sheet & Liquidity

Debt/Equity
0.53
Quick Ratio
0.91
Current Ratio
1.05
Debt
₹130.34 Cr
Total Assets
₹448.12 Cr
Current Assets
₹62.58 Cr
Working Capital
₹2.93 Cr

Ownership

Promoter Holding
61.97%
Chg in Prom Hold
12.87%
FII / Inst Holding
22.15%
Chg in FII Hold
-14.45%

Financial Snapshot

Enterprise Value
₹1,363.21 Cr
Total Revenue (TTM)
₹310.41 Cr
EBITDA
₹98.56 Cr
Free Cash Flow
₹14.48 Cr
Operating Cash Flow
₹81.83 Cr
Shares Outstanding
₹5.21 Cr
Gross Margin
88.25%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SURAKSHA SURAKSHA DIAGNOSTIC LTD NSEPHARMA 261.75 43.84 ₹1,363.21 Cr 0.19% 14.70% 13.15% 17.75% 70.31%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 60.05 Cr51.82 Cr55.19 Cr60.73 Cr66.75 Cr59.51 Cr65.09 Cr72.59 Cr78.73 Cr77.69 Cr81.41 Cr
Cost of Revenue ------8.85 Cr8.75 Cr8.90 Cr8.67 Cr10.16 Cr
Gross Profit ------56.25 Cr63.84 Cr69.83 Cr69.02 Cr71.25 Cr
Operating Expenses 39.22 Cr36.50 Cr35.72 Cr40.12 Cr43.55 Cr41.26 Cr44.99 Cr50.46 Cr55.65 Cr55.57 Cr57.85 Cr
Operating Income 12.88 Cr7.40 Cr11.11 Cr11.62 Cr14.45 Cr9.42 Cr11.26 Cr13.38 Cr14.18 Cr13.45 Cr13.41 Cr
EBITDA 20.83 Cr15.32 Cr19.47 Cr20.61 Cr23.20 Cr18.25 Cr20.00 Cr24.66 Cr24.97 Cr23.78 Cr25.15 Cr
Interest Expense 2.48 Cr2.03 Cr2.08 Cr2.22 Cr2.13 Cr1.98 Cr2.06 Cr2.70 Cr2.78 Cr3.16 Cr3.92 Cr
Pretax Income 10.96 Cr6.22 Cr9.23 Cr10.52 Cr13.63 Cr8.04 Cr9.21 Cr12.47 Cr12.05 Cr10.06 Cr9.98 Cr
Tax Provision 2.63 Cr1.68 Cr2.91 Cr2.84 Cr3.48 Cr2.06 Cr2.04 Cr3.29 Cr3.22 Cr2.82 Cr3.82 Cr
Net Income 8.34 Cr4.53 Cr6.32 Cr7.67 Cr10.15 Cr5.98 Cr7.39 Cr9.40 Cr8.99 Cr7.52 Cr6.28 Cr
Diluted EPS 121.8867.3994.491.842.401.181.421.801.731.441.21

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 158.00 Cr140.00 Cr-190.13 Cr218.71 Cr252.09 Cr310.41 Cr
Cost of Revenue ---27.40 Cr27.25 Cr29.52 Cr36.48 Cr
Gross Profit ---162.73 Cr191.46 Cr222.57 Cr273.94 Cr
Operating Expenses 123.00 Cr115.00 Cr-146.95 Cr150.49 Cr174.44 Cr219.53 Cr
Operating Income 21.00 Cr9.00 Cr-15.78 Cr40.97 Cr48.13 Cr54.41 Cr
EBITDA 34.00 Cr25.00 Cr-47.48 Cr72.84 Cr85.09 Cr98.56 Cr
Interest Expense 2.00 Cr2.00 Cr-9.06 Cr8.79 Cr8.39 Cr12.55 Cr
Pretax Income 21.00 Cr6.00 Cr-6.75 Cr31.45 Cr41.41 Cr44.56 Cr
Tax Provision 5.88 Cr-6.00 L-68.30 L8.33 Cr10.43 Cr13.15 Cr
Net Income 15.00 Cr6.00 Cr-6.52 Cr23.63 Cr31.82 Cr32.19 Cr
Diluted EPS 220.4393.334.001.254.545.97-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 173.00 Cr171.00 Cr-281.19 Cr300.20 Cr333.52 Cr448.12 Cr
Current Assets ---68.05 Cr72.45 Cr47.15 Cr62.58 Cr
Cash & Equivalents ---2.16 Cr2.52 Cr2.25 Cr3.21 Cr
Inventory ---6.16 Cr6.68 Cr8.05 Cr8.14 Cr
Receivables ---4.68 Cr8.87 Cr13.81 Cr22.76 Cr
Total Liabilities ---125.73 Cr121.06 Cr123.29 Cr204.64 Cr
Current Liabilities ---38.34 Cr39.41 Cr42.72 Cr59.65 Cr
Long Term Debt ---8.44 Cr5.18 Cr2.88 Cr17.76 L
Total Debt 13.00 Cr18.00 Cr-96.87 Cr90.48 Cr88.89 Cr130.34 Cr
Total Equity 118.00 Cr125.00 Cr-155.93 Cr179.41 Cr211.24 Cr244.85 Cr
Shares Outstanding ---5.21 Cr5.21 Cr5.21 Cr5.21 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 31.00 Cr24.00 Cr-44.10 Cr60.48 Cr63.36 Cr81.83 Cr
Investing Cash Flow -20.00 Cr-28.00 Cr--20.80 Cr-35.00 Cr-39.58 Cr-52.17 Cr
Financing Cash Flow -10.00 Cr3.00 Cr--24.33 Cr-25.13 Cr-24.05 Cr-28.69 Cr
Capital Expenditure -16.00 Cr-16.00 Cr--13.17 Cr-45.47 Cr-42.02 Cr-67.34 Cr
Free Cash Flow 15.00 Cr8.00 Cr-30.93 Cr15.01 Cr21.34 Cr14.48 Cr
Net Change in Cash 1.00 Cr-1.00 Cr--1.03 Cr35.74 L-27.32 L96.73 L

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---85.6%87.5%88.3%88.2%
Operating Margin % 13.3%6.4%-8.3%18.7%19.1%17.5%
Net Margin % 9.5%4.3%-3.4%10.8%12.6%10.4%
ROE % 12.7%4.8%-4.2%13.2%15.1%13.1%
ROCE % ---6.5%15.7%16.6%14.0%

Shareholding Pattern

Insiders
61.97%
Institutions
22.15%
Public Float
58.25%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SURAKSHA

Google News Fri, 22 May 2026

Suraksha Diagnostic Q4 Profit Slips to ₹6.3 Cr Despite 25% Revenue Growth to ₹81.4 Cr - Sahi

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQQ1BGZlc0S2VFX1FjamExUVZEdXdhNjFfTXZ3SjF4Z1RQZUs3UkRjMXNuSTFQMFRIVFpOSEh3TVFIY1lqQzA1U0Nyd2pPWXhWSkVQX01IUzRIR3VHWWx0aEpqeW41WG1IamhoQ2pYb21FV25McHBqaFJ4dXo0YXZicERPRW1fektwazJyOW…

Google News Wed, 27 May 2026

Suraksha FY26 revenue rises 22.5%, dividend recommended - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPVWlDdGtCTjJuMGlRcEdIWFF4VTNSZ0lEVU5EQU4zcDdiLWNxaDRyaGdMempzcTROOUxoVDZyN29WSHhIMFhzZU9WNUFiaWY0VElSWkpjUXhNeFVBX3RJLWM4ZWdCQllmOG9LUDhabm56cVJ4TGJFVUFaeHFGUDI0Mk1hQ2kwOVhjZ01sbj…

Google News Mon, 15 Jun 2026

Suraksha Diagnostic closes trading window for Q1FY27 results - scanx.trade

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNVDl6QmIzU1ZBMmQ2dzRlR0t2UHZXZW12Y1pTY2MyMmN2RzF6cUNTOHY1NU5OTDJJeUlFLU1GMEg2UXB1RDN0THgwcmp3SUd3b3U2X19JdmtfZnNkOXZmNnFyTW55bDR2V0tTRHJLS0dwVXQ2MkpvLU9EOHNZZFMyWHZtN3dBNEtHamlhVm…

Google News Mon, 16 Feb 2026

Suraksha Diagnostic IPO subscribed 1.27 times on last day; Steps to check allotment status online and listing date - Upstox

<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxOYXg5V25iV1Vfc2FMd3lqdkxPRm1RS0NHM0RRa3ZQUk5zNGZkSzUxRmtUMWU0VmM5bnNxb3l6ODc3VDlQRWxtZ0F1d2k0LXg5OWo0WURjWHY0UUc2MUs1QXhPRFNSR1ZITXZRS1hpUC1lMmNVT3RzMGtKSGExYWN1eXRYMkU2RHV4U19YVm…

Google News ue, 09 Jun 2026

Suraksha Diagnostic Company Secretary resigns effective July 15 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQV2diVzFqRWpEX1NQbjduS2cyVUd2UGRoVktETjl4bjNDcTZ1NUgwLWlfbXNqc3ZTbnQ4MUtQWVlPZGJkd1FGbXZoLUVjMVFIWERlZlNKTHE0LXo3UmtqVHFDcExua0VwUG9QQk02MWVoTlRvVDZlRDQtUDhyZzdlbjRaeFQ2RG9oZTZ4dV…

Google News hu, 28 Nov 2024

Suraksha Diagnostic IPO: Key points you need to know - Value Research

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPV3BUV3FBcl9hdVgzV0lueVZIOXdHMG1VTWJqWEZZdzVaWkswenNLTEtQdUwtYUFTWUdiSjFldGxEYUlCMGE4X0p6Z0JLc2E3dHhZa2RLQUlpR1dxM1U4VjJPZ0JfOTIxNFZ2MUpMQXd3UUt0ZjdSSEVzZWZJVzhvcTBhTHN5QS1BUHg5Wm…

SURAKSHA — Frequently Asked Questions

What is the current share price of SURAKSHA DIAGNOSTIC LTD (SURAKSHA)?

As of 2026-07-15 09:52 IST, SURAKSHA DIAGNOSTIC LTD (SURAKSHA) trades at ₹261.75 on NSE. Its 52-week range is ₹227.95 to ₹327.90.

What is the market capitalisation of SURAKSHA?

SURAKSHA DIAGNOSTIC LTD (SURAKSHA) has a market capitalisation of ₹1,363.21 Cr on NSE.

What is the P/E ratio of SURAKSHA?

SURAKSHA trades at a trailing price-to-earnings (P/E) ratio of 43.84. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.53.

Does SURAKSHA pay a dividend?

SURAKSHA DIAGNOSTIC LTD (SURAKSHA) currently offers a dividend yield of 0.19%.

What is the return on equity (ROE) of SURAKSHA?

SURAKSHA has a return on equity (ROE) of 13.15%. Its return on capital employed (ROCE) is 14.70%.

Is SURAKSHA a good stock to buy?

This page provides a data-driven analysis of SURAKSHA DIAGNOSTIC LTD (SURAKSHA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space